Determinants of Antibody Levels and Protection against Omicron BQ.1/XBB Breakthrough Infection

Publication date: Oct 10, 2024

The ongoing evolution of SARS-CoV-2, particularly through the emergence of new variants, continues to challenge our understanding of immune protection. While antibody levels correlate with protection against earlier variants like Alpha and Delta, their relationship with Omicron sub-variants remains unclear. To investigate the role of antibody levels and neutralizing activity in preventing breakthrough infections, we analyzed longitudinal SARS-CoV-2 humoral responses and neutralizing activity against the ancestral virus and major emerging variants in a well-characterized cohort of healthcare workers in Spain (N = 405). We found that antibody levels and neutralization titers are key indicators of protection against SARS-CoV-2, including the BQ.1 and XBB Omicron variants. Higher IgG and IgA levels were associated with protection over three 6-month follow-up periods sequentially dominated by BA.1, BA.2, BA.5, BQ.1, and XBB Omicron sub-variants, although the strength of the association between antibody levels and protection declined over time. Our findings demonstrate that binding antibody levels and neutralizing responses are a valid correlate of protection against more evasive BQ.1 and XBB Omicron variants, although the strength of this association declined over time. Additionally, our results underscore the importance of continuous monitoring and updating vaccination strategies to maintain effective protection against emerging SARS-CoV-2 variants.

PDF

Concepts Keywords
100046tc21_2022 Antibody
Canada Ba
Immunization Cov
Infection1517 Fig
June Higher
Igg
Infection
Infections
Omicron
Protection
Rbd
Sars
T10
T11
Variants

Semantics

Type Source Name
disease MESH Breakthrough Infection
disease IDO role
disease MESH Infectious Diseases
disease MESH Chronic Diseases
disease MESH COVID 19 pandemic
disease MESH infection
disease MESH asymptomatic infections
disease IDO immune response
drug DRUGBANK Isopropyl beta-D-thiogalactopyranoside
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Tromethamine
drug DRUGBANK Immune Globulin Human
disease IDO assay
disease IDO reagent
disease IDO process
drug DRUGBANK Hyaluronic acid
disease MESH tic
drug DRUGBANK Penciclovir
disease MESH privacy
drug DRUGBANK Erythropoietin

Download Document

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *